Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Hypertension
Interventions: 6R-BH4 (sapropterin dihydrochloride); Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 24
States / cities: Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 21 more

Conditions: Exercise Performance, Exercise Recovery, Cognitive Function, Nitric Oxide, Blood Flow, Endurance Exercise
Interventions: 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation, Placebo, 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: HIV Infection
Interventions: Aspirin 325mg, Antiretroviral therapy (ART); Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetic Macular Edema, Cataract
Interventions: Aflibercept injected Pre- and Post-operatively, Aflibercept injected intraoperatively; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Transgenderism, Insulin Sensitivity/Resistance, Endothelial Dysfunction, Vascular Stiffness
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Years to 14 Years · Male only
Enrollment: 30 participants
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer
Interventions: flow cytometry, immunoenzyme technique, laboratory biomarker analysis; Other
Lead sponsor: University of Arizona; Other
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Osteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions: Bevacizumab, Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, etoposide, Surgery, Radiotherapy; Biological · Drug · Procedure + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 30 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 5
States / cities: San Diego, California • Baltimore, Maryland • Bethesda, Maryland + 2 more

Conditions: Endothelial Dysfunction
Interventions: Creatine Monohydrate, Maltodextrin (Placebo); Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Diabetic Macular Edema
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 40
States / cities: Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more

Conditions: Metabolic Syndrome
Interventions: exercise, Diagnostics, Inhaled CO2-mixed air; Behavioral · Diagnostic Test · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metabolic Syndrome, Obesity
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Endothelial Dysfunction
Interventions: Not listed
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: AIDS
Interventions: Tenofovir, Rilpivirine, Prezcobix, Dolutegravir; Drug
Lead sponsor: Sabyasachi Sen; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Heart Failure
Interventions: LOVAZA (Omega-3), Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Injury, Proteinuria, Hypertension
Interventions: Isosorbide Mononitrate, Placebo oral tablet; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adverse Childhood Experience, Endothelial Function (FMD), Endothelial Injury, Mitochondrial Function, Oxidative Stress, Psychosocial Influence on Cardiovascular Disease
Interventions: Mitoquinone mesylate (MitoQ), Placebo; Dietary Supplement
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 29 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Endothelial Dysfunction, Insulin Resistance, Metabolic Syndrome, Peripheral Arterial Disease
Interventions: Fish Oil (Omega-3 Fatty Acids); Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute ST Elevation Myocardial Infarction
Interventions: Epoetin alfa; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 21 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 16
States / cities: Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 11 more

Conditions: Preeclampsia Postpartum
Interventions: Aspirin tablet, Placebo oral capsule; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Cell Carcinoma
Interventions: Belzutifan, Zanzalintinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: San Francisco, California • Mineola, New York • New York, New York + 3 more

Conditions: Obesity, Overweight
Interventions: Active Concord Grape Juice 12 oz per day, Placebo Grape Juice 12 oz per day; Other
Lead sponsor: Boston University; Other
Eligibility: 50 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: High sodium, Low sodium; Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Macular Edema
Interventions: intravitreal ranibizumab 0.3 mg, dexamethasone intravitreal implant, Sham injection; Drug · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 56
States / cities: Beverly Hills, California • Huntington Beach, California • Loma Linda, California + 47 more

Conditions: Retinal Diseases
Interventions: Not listed
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Search by objective public record fields.

A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension

Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

Aspirin and Antiretroviral Therapy in HIV Infected Patients

Cataract DME - Peri vs. Intraop

Puberty Suppression and Cardiometabolic Health

Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Exercise and Carotid Artery Function in Metabolic Syndrome

Study of Sildenafil Citrate on Insulin Resistance in African American

Endothelial Dysfunction As A Predictor Of Perioperative Outcome

Effect on HIV Medications on EPC Cells

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury

Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity

The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

Postpartum Low-Dose Aspirin and Preeclampsia

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Effect of Concord Grape Juice on Endothelial Function

Dietary Salt Intake and Vascular Function

Phase II Combination Steroid and Anti-VEGF for Persistent DME

Measuring Corneal Cells With Specular Microscopy